A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus.

ABSTRACT:

Aim

of the study: Decompensated hepatitis C virus (HCV) cirrhosis is a difficult to treat cohort, and there is no gold standard predictor of response to direct-acting antiviral (DAA) therapy. We conducted this study to look for factors responsible for improvement in post-therapy status, i.e. attainment of Child-Turcotte-Pugh (CTP) class A from B or C, and devise a new model to predict post-therapy response.

Material

and methods: Prospective analysis of data from decompensated HCV cirrhotics was done and association of each parameter with patient outcomes at 36 weeks after treatment was assessed.

Results

34 patients (54.8%) attained CTP class A after treatment. Factors that were independently associated with disease outcome included albumin (odds ratio [O

SUBMITTER: Debnath P 

PROVIDER: S-EPMC7592091 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature